1. Home
  2. PTCT
  3. PTCT News

Latest PTC Therapeutics Inc. (PTCT) News on January 23, 2025

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTCT

PR Newswire

9 days ago

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference
PTCT

PR Newswire

10 days ago

PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference

PTCT

MT Newswires

16 days ago

RBC Cuts Price Target on PTC Therapeutics to $58 From $63, Keeps Outperform Rating

PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PTCT

PR Newswire

a month ago

PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

PTCT

MT Newswires

a month ago

PTC Therapeutics Files NDA With US FDA for Vatiquinone to Treat Friedreich's Ataxia

PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
PTCT

PR Newswire

a month ago

PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTCT

PR Newswire

a month ago

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTCT

MT Newswires

a month ago

Morgan Stanley Upgrades PTC Therapeutics to Overweight From Equalweight, Raises Price Target to $67 From $45

UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug
PTCT

Investor's Business Daily

a month ago

UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug

UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug
PTCT

Investor's Business Daily

a month ago

UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug

PTC Therapeutics price target raised to $71 from $47 at UBS
PTCT

TipRanks

2 months ago

PTC Therapeutics price target raised to $71 from $47 at UBS

Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
PTCT

Zacks

2 months ago

Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy
PTCT

Zacks

2 months ago

PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

PTCT

MT Newswires

2 months ago

UBS Raises PTC Therapeutics Price Target to $71 From $47, Maintains Buy Rating

PTCT

MT Newswires

2 months ago

RBC Upgrades PTC Therapeutics to Outperform From Sector Perform, Raises Price Target to $63 From $39

Novartis and PTC Therapeutics link to develop Huntington’s therapy
PTCT

Pharmaceutical Technology

2 months ago

Novartis and PTC Therapeutics link to develop Huntington’s therapy

PTCT

MT Newswires

2 months ago

Sector Update: Health Care Stocks Slipping Late Afternoon

PTCT

MT Newswires

2 months ago

Sector Update: Health Care

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
PTCT

Benzinga

2 months ago

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

PTC Therapeutics Stock Soars on Novartis Licensing Agreement
PTCT

Investopedia

2 months ago

PTC Therapeutics Stock Soars on Novartis Licensing Agreement

Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14%
PTCT

GuruFocus.com

2 months ago

Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14%

PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate
PTCT

MT Newswires

2 months ago

PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
PTCT

Investor's Business Daily

2 months ago

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone

PTCT

MT Newswires

2 months ago

Sector Update: Health Care Stocks Mixed Pre-Bell Monday

PTCT

MT Newswires

2 months ago

Sector Update: Health Care

PTCT

MT Newswires

2 months ago

PTC Therapeutics Signs Exclusive Global License Deal With Novartis Unit for PTC518 Huntington's Disease Program; Shares Rise Premarket

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
PTCT

PR Newswire

2 months ago

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

PTC Therapeutics to sell Priority Review Voucher for $150M
PTCT

TipRanks

2 months ago

PTC Therapeutics to sell Priority Review Voucher for $150M

PTC Therapeutics ALS drug fails to meet endpoints as trials shut down
PTCT

Clinical Trials Arena

2 months ago

PTC Therapeutics ALS drug fails to meet endpoints as trials shut down

PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs
PTCT

Benzinga

2 months ago

PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs

PTCT

MT Newswires

2 months ago

PTC Therapeutics to Sell Rare Pediatric Disease Voucher for $150 Million

PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million
PTCT

PR Newswire

2 months ago

PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million

Kronos, Idorsia plan layoffs; PTC shelves ALS drug
PTCT

BioPharma Dive

2 months ago

Kronos, Idorsia plan layoffs; PTC shelves ALS drug

PTCT

MT Newswires

2 months ago

PTC Therapeutics' Amyotrophic Lateral Sclerosis Trial Fails to Meet Endpoints; Shares Fall After Hours

PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients
PTCT

PR Newswire

2 months ago

PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTCT

PR Newswire

2 months ago

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain
PTCT

Benzinga

2 months ago

FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain

FDA grants accelerated approval for PTC’s AADC deficiency gene therapy
PTCT

Pharmaceutical Technology

2 months ago

FDA grants accelerated approval for PTC’s AADC deficiency gene therapy

PTCT

MT Newswires

2 months ago

Sector Update: Health Care Stocks Advance Pre-Bell Thursday

PTC wins US approval of gene therapy for fatal enzyme disorder
PTCT

BioPharma Dive

2 months ago

PTC wins US approval of gene therapy for fatal enzyme disorder

PTCT

MT Newswires

2 months ago

PTC Therapeutics Receives FDA Acceslerated Approval for Rare Brain Disease Deficiency Treatment

PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy
PTCT

PR Newswire

2 months ago

PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy

PTC Therapeutics Third Quarter 2024 Earnings: Beats Expectations
PTCT

Simply Wall St.

2 months ago

PTC Therapeutics Third Quarter 2024 Earnings: Beats Expectations

PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
PTCT

GuruFocus.com

2 months ago

PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...

PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
PTCT

Zacks

2 months ago

PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates
PTCT

Zacks

2 months ago

PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates

PTCT

Associated Press Finance

2 months ago

PTC Therapeutics: Q3 Earnings Snapshot

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
PTCT

PR Newswire

2 months ago

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Unlocking Q3 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics
PTCT

Zacks

3 months ago

Unlocking Q3 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics

PTC Therapeutics Inc (PTCT) Q3 2024: Everything You Need To Know Ahead Of Earnings
PTCT

GuruFocus.com

3 months ago

PTC Therapeutics Inc (PTCT) Q3 2024: Everything You Need To Know Ahead Of Earnings

PTC Therapeutics to Participate at Upcoming Investor Conferences
PTCT

PR Newswire

3 months ago

PTC Therapeutics to Participate at Upcoming Investor Conferences

Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug
PTCT

BioPharma Dive

3 months ago

Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug

PTCT

MT Newswires

3 months ago

PTC Therapeutics New Drug Application Resubmission for Translarna Accepted for FDA Review

PTC Therapeutics (NASDAQ:PTCT) grows 8.1% this week, taking one-year gains to 127%
PTCT

Simply Wall St.

3 months ago

PTC Therapeutics (NASDAQ:PTCT) grows 8.1% this week, taking one-year gains to 127%

PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission
PTCT

PR Newswire

3 months ago

PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTCT

PR Newswire

3 months ago

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results
PTCT

PR Newswire

3 months ago

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results

Analysts Estimate Stevanato Group (STVN) to Report a Decline in Earnings: What to Look Out for
PTCT

Zacks

3 months ago

Analysts Estimate Stevanato Group (STVN) to Report a Decline in Earnings: What to Look Out for

State Street Corp's Strategic Acquisition in PTC Therapeutics Inc
PTCT

GuruFocus.com

3 months ago

State Street Corp's Strategic Acquisition in PTC Therapeutics Inc

PTCT

MT Newswires

3 months ago

PTC Therapeutics Says EU Regulator Maintained Negative Opinion on Translarna Marketing Renewal

PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug
PTCT

BioPharma Dive

3 months ago

PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug

CHMP Maintains Negative Opinion on Translarna™ Reexamination
PTCT

PR Newswire

3 months ago

CHMP Maintains Negative Opinion on Translarna™ Reexamination

Will PTC Therapeutics (PTCT) Report Negative Q3 Earnings? What You Should Know
PTCT

Zacks

3 months ago

Will PTC Therapeutics (PTCT) Report Negative Q3 Earnings? What You Should Know

PTCT

MT Newswires

3 months ago

PTC Therapeutics Gets FDA Drug Review Date for Phenylketonuria Treatment

PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results
PTCT

PR Newswire

3 months ago

PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results

PTC Therapeutics Inc (PTCT) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
PTCT

GuruFocus.com

3 months ago

PTC Therapeutics Inc (PTCT) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...

PTC Therapeutics (PTCT) Surges 16.5%: Is This an Indication of Further Gains?
PTCT

Zacks

3 months ago

PTC Therapeutics (PTCT) Surges 16.5%: Is This an Indication of Further Gains?

PTCT Stock Rises on Positive Updates on Friedreich Ataxia Program
PTCT

Zacks

3 months ago

PTCT Stock Rises on Positive Updates on Friedreich Ataxia Program

PTCT

MT Newswires

3 months ago

Sector Update: Health Care Stocks Rise Late Afternoon

PTCT

MT Newswires

3 months ago

Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon

PTCT

MT Newswires

3 months ago

Update: PTC Therapeutics Reports 'Positive' Updates on Neurodegenerative Disorder Treatment Candidate; Shares Jump

PTCT

MT Newswires

3 months ago

PTC Therapeutics Reports 'Positive' Updates on Neurodegenerative Disorder Treatment Candidate; Shares Jump

PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program
PTCT

PR Newswire

3 months ago

PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program

PTCT

MT Newswires

4 months ago

RBC Lifts Price Target on PTC Therapeutics to $34 From $32, Keeps Sector Perform Rating

3 Top Stocks That Could Still Rocket Higher in 2024
PTCT

Motley Fool

4 months ago

3 Top Stocks That Could Still Rocket Higher in 2024

PTCT

MT Newswires

4 months ago

PTC Therapeutics' New Drug Application for Phenylketonuria Treatment Sepiapterin Gets Accepted by FDA

PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients
PTCT

PR Newswire

4 months ago

PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients

5 FDA decisions to watch in the fourth quarter
PTCT

BioPharma Dive

4 months ago

5 FDA decisions to watch in the fourth quarter

PTCT

MT Newswires

4 months ago

PTC Therapeutics Granted FDA Fast Track Designation for Huntington's Disease Program

FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
PTCT

PR Newswire

4 months ago

FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTCT

PR Newswire

4 months ago

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics to Participate at Upcoming Investor Conferences
PTCT

PR Newswire

5 months ago

PTC Therapeutics to Participate at Upcoming Investor Conferences

PTCT

MT Newswires

5 months ago

ClearPoint Neuro Repays $10 Million Convertible Note Early

PTCT

MT Newswires

5 months ago

PTC Therapeutics Has Upside Potential With Multiple Upcoming Catalysts, UBS Says

PTCT

MT Newswires

5 months ago

UBS Upgrades PTC Therapeutics to Buy From Neutral, $47 Price Target

PTC Therapeutics Stock Earns RS Rating Upgrade To 83
PTCT

Investor's Business Daily

5 months ago

PTC Therapeutics Stock Earns RS Rating Upgrade To 83

PTC Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
PTCT

Simply Wall St.

5 months ago

PTC Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates
PTCT

Zacks

5 months ago

PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates

PTCT

Associated Press Finance

5 months ago

PTC Therapeutics: Q2 Earnings Snapshot

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
PTCT

PR Newswire

5 months ago

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Unlocking Q2 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics
PTCT

Zacks

6 months ago

Unlocking Q2 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics

Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
PTCT

Zacks

6 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

PTCT

MT Newswires

6 months ago

PTC Therapeutics Submits New Drug Application to US FDA for Metabolic Disorder Treatment

PTC Therapeutics Announces Sepiapterin NDA Submission to FDA
PTCT

PR Newswire

6 months ago

PTC Therapeutics Announces Sepiapterin NDA Submission to FDA

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results
PTCT

PR Newswire

6 months ago

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results

Will PTC Therapeutics (PTCT) Report Negative Q2 Earnings? What You Should Know
PTCT

Zacks

6 months ago

Will PTC Therapeutics (PTCT) Report Negative Q2 Earnings? What You Should Know

PTCT

MT Newswires

6 months ago

RBC Cuts Price Target on PTC Therapeutics to $32 From $39, Keeps Sector Perform Rating

PTCT

MT Newswires

7 months ago

Cantor Fitzgerald Raises Price Target on PTC Therapeutics to $62 From $52, Maintains Overweight Rating

PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
PTCT

Zacks

7 months ago

PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug

PTC's Journey Of 'Twist And Doubt' Continues With Another Rejection; Shares Tumble
PTCT

Investor's Business Daily

7 months ago

PTC's Journey Of 'Twist And Doubt' Continues With Another Rejection; Shares Tumble

Share on Social Networks: